Introduction {#sec1_1}
============

Multicentric reticulohistiocytosis (MRH) is a rare multisystem syndrome characterized by polyarthritis and papulonodular skin lesions with typical dermal infiltration of histiocytes and multinucleated giant cells. The disease may involve the skin, tendon sheath, synovium, bone, liver, salivary gland, kidney, lymph node, heart and lung. In MRH, an association with hyperlipidemia (30--58%), a positive skin tuberculin test (12--50%), systemic vasculitis and autoimmune disease has been described \[[@B1]\].

Of utmost clinical importance is the association of MRH with a variety of underlying internal malignancies. Such an association has been documented in up to 28% of all reported cases in the world literature, the most common being bronchial, breast, stomach, and cervical carcinomas \[[@B2]\]. Here, we report, for the first time, a case of MRH presenting with liver carcinoma, thus highlighting the association of MRH with malignant disease.

Case Report {#sec1_2}
===========

A 61-year-old man presented with a 4-month history of a nonpruritic rash, which started on his forearm and face after sun exposure and subsequently spread to the ear, scalp and upper chest, after which asymptomatic skin lesions appeared on the lateral margin of his finger. The patient denied any history of photosensitivity but complained of low-grade fever and painful swelling of the joints in his wrist, knee and ankle, accompanied by restricted activity for 1 month. He had a sensation of a foreign body in his pharynx with difficulty in swallowing for about 1 month.

The patient also had a history of hepatitis B, which was diagnosed in the 1970\'s, and severe knee joint pain with bony spurs, which were confirmed by X-ray, for at least 2 years. There was no history of drug allergy, operation, trauma or inherited disease. Treatment with hydroxychloroquine and thalidomide for solar dermatitis in other hospitals showed no therapeutic effect.

Physical examination showed a confluent erythematous eruption affecting his scalp, face, neck and the extensor aspect of his forearm, which was characterized by ruby-red, translucent and grouped papules (fig. [1a](#F1){ref-type="fig"}) that were 0.5 mm to 1 cm in diameter. Red nodules could also be found on the dorsum of the nose, lateral area of the fingers and tongue tip (fig. [1b](#F1){ref-type="fig"}). Musculoskeletal examination revealed a painful swelling of the wrist and knee joints. The results of the clinical examination were otherwise unremarkable.

An extensive laboratory evaluation, including white cell count, urinalysis, stool studies, renal function, electrolytes, cholesterol and triglycerides, erythrocyte sedimentation rate, antistreptolysin O level, rheumatoid factor and antinuclear antibody were normal. Liver function tests including AST 34 U/l (\<30 U/l), ALT 125 U/l (\<50 U/l), ALP 159 U/l (35--104 U/l), GGT 100 U/l (3--45 U/l), total bilirubin 30 µmol/l (3.4--20.4 µmol/l), TBA 21 µmol/l (\<6.8 µmol/l) and total protein, albumin and globulin were normal. Hepatitis index studies showed HBsAg(+), HBsAb \<0.2 IU/l (\>10 IU/l), HBeAb(+), HBsAb \< HBeAg(--), HBeAb(+), HBcAb(+), HBcIgM(--), HAVIgM(--) and HCV(--). The AFP level was significantly elevated (6,820 µg/l, normal range \<10 µg/l). Type-B ultrasonic examination revealed a solid tumor (91 × 69 mm) on the right lobe of the liver, which was suspected to be a small hepatocellular carcinoma.

Treatment with hydroxychloroquine and thalidomide were ineffective. The patient then received hepatic arterial chemoembolization followed by percutaneous transhepatic cholangiography drainage. Five-FU, Oxaliplatin and THP were used as anticancer drugs. The AFP level after the interventional treatment was 1,027.5 µg/l, and the tumor mass decreased to 67 × 66 mm. The cutaneous symptoms improved significantly within 1 month (several large nodules disappeared immediately; later, the erythematous rash and grouped papules resolved and the patient\'s arthralgia and swelling of joints gradually improved).

Skin biopsy on the right forearm showed infiltration of the dermis with polymorphic histiocytes and giant cells with 'ground glass' cytoplasm lying between collagen bundles (fig. [2a](#F2){ref-type="fig"}). The histiocytic marker CD68 was positive, as were leukocyte common antigen, HLA-DR, lysozyme and vimentin (fig. [2b, c](#F2){ref-type="fig"}). Langerhans cell markers (S-100 and CD1a) were negative and the histological appearances were consistent with MRH.

Discussion {#sec1_3}
==========

MRH, often referred to as lipoid dermato-arthritis, was first reported in 1937 by Weber and Freudenthal \[[@B3]\]. MRH is so rare that fewer than 300 cases have been reported in the literature. In 1969, Barrow and Holubar \[[@B4]\] first raised the question of whether there was an association between MRH and malignancy. They found 5 cases of cancer in 33 patients (15%). Snow and Muller \[[@B5]\] reported a malignancy rate of 25% in 133 cases of MRH reported in the literature until 1994. The malignancies were most commonly hematological, breast or stomach carcinomas.

Eleven \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12], [@B13], [@B14], [@B15]\] of the 66 cases we reviewed (English-language literature from 1995 until now) had cancer and were evaluated for the following parameters: age, sex, type of neoplasm at presentation, duration preceding or following the diagnosis of cancer that MRH developed and treatment response of both the tumor and MRH. The results are presented in table [1](#T1){ref-type="table"} (including the present case). For most of these cases (including the present case), the onset of malignancy and MRH occurred within approximately 3 years, and in some cases, the onset of MRH also occurred in close proximity to the time of recurrence of a previously diagnosed malignancy \[[@B13], [@B15]\].

This is the first case report of MRH with liver carcinoma. Although the etiology of MRH is unknown, the possibility that MRH reflects a constellation of symptoms seen within paraneoplastic syndrome is supported by the frequency of associated neoplasm (18% based on our review), the remission of the lesions after tumor treatment (6 of 12 cases \[[@B6], [@B7], [@B8], [@B10], [@B11], [@B12]\]) and the onset of MRH just prior to the relapse of the neoplasm (case No. 8 \[[@B11]\] of table [1](#T1){ref-type="table"}). Therefore, all patients with MRH should be evaluated and monitored carefully.

![**a** Multiple fusion ruby-red papulonodular eruption in the neck, extensor aspect of the forearm and chest (sharply demarcated). **b** Light pink and shiny nodule on philtrum and tongue tip.](cde-0004-0163-g01){#F1}

![**a** H&E section showing a prominent dermal histocytic infiltrate with typical 'ground glass' cytoplasm (×200). Skin samples obtained were studied by immunohistochemical staining. CD68 staining (**b**) and also Vim positive cells (**c**) were observed in some histocytes (Envision, ×400).](cde-0004-0163-g02){#F2}

###### 

Review of cases of malignancy-associated MRH in the English-language literature

  Case No.           Sex/age years   Type of malignancy                    Time of malignancy relative to MRH[^a^](#T1F1){ref-type="table-fn"}   Treatment                                              Response to treatment   Outcome               
  ------------------ --------------- ------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------ ----------------------- --------------- ----- ---------------------------------------------------
  1 (present case)   M/61            liver cancer                          \+ 4 months                                                           \(1\) immunosuppressive agent                          --                      NSC                   MRH: improved malignancy: PR
                                                                                                                                                 \(2\) hepatic arterial chemoembolizaion                PR                      GI              GI    
                                                                                                                                                 \(3\) PCTD external drainage                           PR                      GI              GI    
                                                                                                                                                                                                                                                      
  2 \[[@B6]\]        F/62            lung cancer                           \+ 1 year                                                             \(1\) steroids                                         --                      CR              PR    no recurrence of MRH and cancer
                                                                                                                                                 \(2\) MTX                                              --                      CR              PR    
                                                                                                                                                 \(3\) right lower lobectomy                            CR                      no recurrence   PR    
                                                                                                                                                                                                                                                      
  3 \[[@B7]\]        F/56            urinary bladder cancer                S                                                                     \(1\) steroids                                         --                      NSC             PR    patient died 1 month later from metastases
                                                                                                                                                 \(2\) cisplatin                                        PR                      PR              --    
                                                                                                                                                 \(3\) etoposide                                        PR                      PR              --    
                                                                                                                                                                                                                                                      
  4 \[[@B7]\]        M/59            renal cancer                          S                                                                     NM                                                     NM                      NM              NM    --
                                                                                                                                                                                                                                                      
  5 \[[@B8]\]        F/33            nasopharyngeal caner                  S                                                                     \(1\) radiotherapy                                     PR                      PR              --    MRH: improved malignancy: NK
                                                                                                                                                 \(2\) cisplatin                                        PR                      PR              --    
                                                                                                                                                                                                                                                      
  6 \[[@B9]\]        M/31            Burkitt lymphoma and adenocarcinoma   −24 years                                                             \(1\) CT                                               PR                      NM              NM    --
                                                                                                                                                 \(2\) radiotherapy                                     PR                      NM              NM    
                                                                                                                                                 NM                                                     NM                      NM              NM    --
                                                                                                                                                                                                                                                      
  7 \[[@B10]\]       F/64            ovarian cancer                        \+ 2 months                                                           \(1\) steroids                                         --                      NSC             GI    MRH: improved malignancy: NR
                                                                                                                                                 \(2\) MTX                                              --                      NSC             GI    
                                                                                                                                                 \(3\) TH                                               CR                      CR              CR    
                                                                                                                                                 \(4\) CT                                               CR                      CR              CR    
                                                                                                                                                                                                                                                      
  8 \[[@B11]\]       F/69            endometrial cancer                    \+ 3 years                                                            \(1\) MTX                                              --                      CR              CR    cancer recurrence 1 year later/MRH coalesce
                                                                                                                                                 \(2\) TH                                               CR                      CR              CR    
                                                                                                                                                 \(3\) CT                                               CR                      CR              CR    
                                                                                                                                                                                                                                                      
  9 \[[@B12]\]       F/70            breast cancer                         \+ 15 years                                                           \(1\) steroids                                         NK                      CR              P     no recurrence of cancer.
                                                                                                                                                 \(2\) MTX                                              NK                      CR              P     
                                                                                                                                                 \(3\) left mastectomy for breast cancer 15 years ago                           --              --    
                                                                                                                                                                                                                                                      
  10 \[[@B13]\]      F/40            breast cancer                         primary: + 2 years recurrence: + 2 months                             \(1\) immunosuppressive agent                          NK                      GI              GI    malignancy: NR
                                                                                                                                                 \(2\) steroids                                         NK                      GI              GI    
                                                                                                                                                                                                                                                      
  11 \[[@B14]\]      F/39            unknown primary tumor                 S                                                                     tamoxifen                                              PR                      NSC             NSC   --
                                                                                                                                                                                                                                                      
  12 \[[@B15]\]      F/65            malignant melanoma                    primary: − 9 years recurrence: + 6 months                             \(1\) steroids                                         P                       PR              P     malignancy: no metastatic lesions during 5 months
                                                                                                                                                 \(2\) cyclophosphamide                                 P                       PR              P     
                                                                                                                                                 \(3\) radical dissection                               CR                      NK              NK    

Malignancy was detected before (--), after (+), or simultaneously (S) with the onset of MRH. NSC = No significant change; GI = gradually improved; PR = partial remission; PCTD = percutaneous transhepatic cholangiography drainage; CR = complete clinical remission; NM = no mention; NK = not known; CT = chemotherapy; TH = total hysterectomy; NR = no remission; P = progression.
